Category: Pharma & Biotech

Invictus MD to Increase Investment in AB Laboratories; AB Laboratories Receives Sales License; AB Laboratories, AB Ventures and Acreage Pharms Target over 26,000 kg Capacity in 2018

SHARE THIS POST Vancouver, BC, January 8, 2018 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1) is pleased to announce that the Company has entered into a Letter of Intent (“LOI”) to make a further strategic investment in the licensed production facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), AB Laboratories Inc. (“AB Labs”) located near Hamilton, Ontario, from its current 33.3% ownership interest to 50%.  Additionally, the Company is pleased to announce that AB Labs has received the amendment to sell dried marijuana under the ACMPR (“Sales License”). AB Labs has now received its Sales License to sell dried marijuana under the ACMPR.  AB Labs has 130 kilograms of dried marijuana in its vault and intends to sell 100% of this inventory in January 2018 to Canopy Growth Corporation (TSX:WEED) initiating its first revenue stream since inception. Dan Kriznic, Chairman and CEO commented, “This is a significant milestone for Invictus MD. We started this company in 2014 with the intention of becoming Canada’s Cannabis Company. AB Labs produces high quality strains, which will meet the increasing demand in the Canadian marketplace. We also expect to receive a sales license for Acreage Pharms Ltd. (“Acreage Pharms”) within the first quarter of 2018.” The terms of the LOI include a direct cash investment in AB Labs for $10 million...

Read More

Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update

SHARE THIS POST Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders – – Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer – – Conference Call to be Held at 8:30 AM Tomorrow, January 4, 2018 – DEVON, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) —  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced that it will concentrate its focus on rare (meeting the US FDA designation of an orphan disease, affecting fewer than 200,000 people in the U.S.) and near-rare (affecting fewer than one million people in the U.S.) neurological and psychiatric (“neuropsychiatric”) disorders with high unmet medical needs. In 2018, the Company intends to develop ZYN002 in a pivotal Phase 2/3 program in Fragile X syndrome (FXS) and in Phase 2 programs in refractory epilepsies, including adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE) in pediatric and adolescent patients. Additionally, the Company plans to initiate Phase 2 development of ZYN001 in Tourette Syndrome by year end 2018. “The decision to concentrate on rare and near-rare neurological and psychiatric disorders is driven by a number of important factors, including the compelling ZYN002 clinical data seen to date in Fragile X syndrome and refractory focal epilepsy and by the opportunities for a more efficient and rapid development and regulatory approval process,” said...

Read More

Vitality Biopharma Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC

SHARE THIS POST THC safety record and prior FDA approval propels Vitality’s prodrug as targeted treatment for pediatric IBD without drug psychoactivity LOS ANGELES, CA – (January 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which enable targeted delivery of THC to the large intestine. THC has been previously reviewed and approved by the U.S. Food & Drug Administration (FDA) under the name dronabinol, and has been established as safe and effective for use with appetite stimulation and for treatment of nausea and vomiting. Vitality’s cannabosides could enable oral delivery of large concentrations of cannabinoids in order to provide therapeutic benefits while reducing or eliminating psychoactivity by limiting entry of THC into the bloodstream or brain. Vitality is focusing initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation, and plans to complete a first-in-man clinical study in the first half of 2018. The treatment indications the Company plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome, a severe form...

Read More

Cannabis Science Negotiates for Major Asset Backed Blockchain Crypto Currency with Cannabis and Many Other Industry Applications

SHARE THIS POST Pre-Sales Launch Expected January 2018 with Similar Bitcoin Type ICO Trading to Follow IRVINE, CA, Dec. 22, 2017 (GLOBE NEWSWIRE) — Cannabis Science, Inc. (OTC Pink: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces it has negotiated an ICO with a major asset backed Blockchain participant. This January 2018 Cannabis Science plans pre-launch sales of our own proprietary blockchain and will commence ICO trading with a unique three symbol trading symbol on a number of blockchain currency exchange markets after pre-launch sales have completed. The Cannabis Science blockchain white papers are being finalized now for January 2018 release. “We have been studying the industry for some time now, we certainly believe that we have found something special for this blockchain arena, not just for the cannabis industry, but for so many unexplored industries and applications.  This endeavor is outstanding for Cannabis Science for a number of reasons as our blockchain currency can be backed with real world assets for additional ICO trading security and comfort. Bitcoin has risen 1500% this year, about 85% in the last few weeks and Futures contracts open as of yesterday. “With Cannabis legal in about 29 states and as many as 6 more on the Ballots for 2018, payment solutions are needed for dispensaries and customers so we plan on integrating the upcoming cryptocurrency to make this...

Read More

Cannabis Science Acquires Second PRE ICO Dispensary

SHARE THIS POST Set to Open Two Cannabis Science PRE ICO Medical Marijuana Dispensaries by the End of This Year in the City of Los Angeles and the San Fernando Valley Area for the Anticipated January 2018 Influx IRVINE, CA , Dec. 20, 2017 (GLOBE NEWSWIRE) — Cannabis Science, Inc. (OTC Pink: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its expansion plans for Cannabis Science Medical Marijuana dispensaries are on schedule. The Company has recently signed agreements to acquire and officially open the first two Cannabis Science PRE ICO Medical Marijuana dispensaries in the city of Los Angeles and the greater San Fernando Valley area of Los Angeles. Both dispensaries are scheduled to open at the end of this year to meet the expected, increased demand in the Los Angeles market from the much-anticipated January 2018 new California recreational market influx. “Opening the first two PRE ICO Dispensaries in Los Angeles by the end of this year is a huge step for Cannabis Science and accelerates our aggressive expansion plans in the Los Angeles area, throughout California, and eventually nationwide,” stated CBIS’ President & CEO, and Co-founder, Mr. Raymond C. Dabney.  “We expect to open several compliant PRE ICO dispensary locations throughout California through numerous means. Our timing could not be better as Los Angeles just passed its recreational marijuana...

Read More

Alliance Growers Closes Private Placement

SHARE THIS POST December 18, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG / FWB: 1LA / WKN: A2DFYX) (“Alliance” or “the Company”) is pleased to announce that its private placement originally announced November 20, 2017 has closed. The Company raised $833,849.83 for the issuance of 7,580,453 Units at a price of $0.11 per Unit. Each Unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to acquire one additional common share in the capital of the Company at a price of $0.21 per share, for a period of two years from the date the Units are issued. The warrants are subject to an acceleration clause after the resale restrictions on the shares have expired. The expiry time of the warrants can be accelerated if the Company’s shares trade at or above a weighted average trading price of $0.30 per share for 10 consecutive trading days. All securities issued pursuant to the placement will be subject to a hold period of four months and one day from the date of closing. The proceeds from this financing will be allocated primarily to the Botany Centre for property acquisition and preliminary planning and development, plus finalization of agreements in other potentially lucrative arrangements in the medical and recreational cannabis space, as well as general working capital. Commenting...

Read More